Drug therapy for Multiple Sclerosis: Ofatumumab is a novel Immunoglobulin 1 ( IgG1) lytic monoclonal antibody (mAb) that specifically binds to the human Cluster of Differentiation 20 (CD20) antigen of which expression is restricted to B lymphocytes from the pre-B cell stage to the plasmacytoid immunoblast stage only. A recent trial with an anti-CD20 mAb (rituximab) demonstrated that targeting B-cells reduces the number of gadolinium-enhancing (GdE) T1 lesions and the relapse rate in relapsing-remitting multiple sclerosis (RRMS). Ofatumumab has been shown to be both well tolerated and efficacious in several indications, including a small, placebo-controlled trial in RRMS using an intravenous (IV) formulation. Future Drug Therapy (Asiaticoside A): Chronic inflammation mediated by activated T cells in CNS results in demyelination, axonal loss and neuronal death in MS. Infiltration and proliferation of CD4+T cellsinto the CNS followed by the activation of microglia and astrocytes resulted in pathological activation of the disease. So, the treatment strategies that can inhibit the activation of microglia and astrocyte have the potentials to inhibit the progression of neuro-inflammation, thereby improving the quality of life of MS patients. Chronic activation of glia results in the production of NO and pro-inflammatory cytokines like IL-1, IL-6 and TNF, which enhance the promotion of more and more activated T cells to the CNS. NO have a major role in the apoptosis of oligodendrocyte than that of astrocyte and microglia during inflammation. The production of NO has direct relation with the permeability of BBB in MS, which will promote inflammatory cells and mediators into CNS [12]. It has a prominent role in inducing conduction block, which emphasis the relation of NO in axonal degeneration in demyelinated neurons. Treatment with Asiaticoside A in LPS induced microglia and astrocyte culture can able to bring down the levels of NO which clearly indicate the ability of Asiaticoside A to lower the NO and thereby preventing the inflammation during MS. TNF have a major role in the pathology of MS, very high levels of TNF were observed near active MS lesions. During inflammation, TNF promote the activation of astrocyte and microglia , enhances BBB permeability, promotes excitatory neurotransmission [19] and synaptic plasticity. Asiaticoside at various concentration can prevent the production of TNF in the LPS induced microglia and astrocyte cultures in a significant manner. This might reduce the progression of inflammation during activation of microglia and astrocyte in CNS. Moreover, Asiaticoside A can provide a neuroprotective effect in controlling the inflammation by inhibiting NO and TNF in early stages of neuro-inflammation. Reference: https://www.sciencedirect.com/science/article/pii/S0753332218320985?via%3Dihub The first paragraph is about the drug therapy for MS, which was approved. And the second to the last paragraph is about the future therapy which has not yet clinically approved. Can you write a 5-sentenced paragraph about what is new about Asiaticoside A, comparing to the old therapy, which is Ofatumumab? Please do not use the exact same words or copy and paste. The reference link is about the Asiaticoside A
Use the order calculator below and get started! Contact our live support team for any assistance or inquiry.
[order_calculator]